^
Association details:
| Biomarker: | EGFR S768dupSVD |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) + Exkivity (mobocertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models
Published date:
08/08/2023
Excerpt:
The combined efficacy of mobocertinib and amivantamab was tested in 2 human patient-derived xenograft (PDX) models expanded from patients with EGFR ex20ins+ NSCLC, namely CTG-2842 (EGFR A767dupASV) and J100672 (EGFR S768dupSVD)….in the J100672 model, amivantamab 30 mg/kg plus mobocertinib 10 mg/kg yielded a GRI of 168%, with significantly reduced tumor volume over monotherapies (P<0.001).